Abstract
The present study assesses whether ranolazine increases left ventricular (LV) function without an increase in myocardial oxygen consumption (MVO2) and thus improves LV mechanical efficiency in dogs with heart failure (HF). Ranolazine did not change MVO2 and LV mechanical efficiency increased (22.4+/-2.8% to 30.9+/-3.4% (P<0.05). In contrast, dobutamine significantly increased MVO2 and did not improve mechanical efficiency. Thus, short-term treatment with ranolazine improved LV function without an increase in MO2, resulting in an increased myocardial mechanical efficiency in dogs with HF.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Acetanilides
-
Animals
-
Cardiotonic Agents / administration & dosage*
-
Chronic Disease
-
Coronary Circulation / drug effects
-
Disease Models, Animal
-
Dobutamine / administration & dosage
-
Dogs
-
Drug Administration Schedule
-
Fatty Acids, Nonesterified / metabolism
-
Glucose / metabolism
-
Heart / drug effects*
-
Heart / physiopathology
-
Heart Failure / drug therapy*
-
Heart Failure / physiopathology
-
Heart Rate / drug effects
-
Lactic Acid / metabolism
-
Myocardium / metabolism
-
Oxygen Consumption / drug effects
-
Piperazines / administration & dosage*
-
Ranolazine
-
Stroke Volume / drug effects
-
Time Factors
-
Treatment Outcome
-
Ventricular Dysfunction, Left / drug therapy
-
Ventricular Dysfunction, Left / physiopathology
Substances
-
Acetanilides
-
Cardiotonic Agents
-
Fatty Acids, Nonesterified
-
Piperazines
-
Lactic Acid
-
Dobutamine
-
Ranolazine
-
Glucose